Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (February 2019)
19 slides from Rhythm Biosciences's investor presentation, Feb 11, 2019
Slide 1: A Medical Diagnostics Technology Company
A Medical Diagnostics Technology Company The creation of a simple, low cost blood test for the early detection of colorectal cancer for the global market Corporate presentation Q1 2019 (ASX: RHY) CONFIDENTIAL 1 © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or unde
Slide 3: Table of contents
Table of contents Corporate overview 4 Board and Management team 5 Introduction: Colorectal Cancer 6 A Global Problem 7 The Problem is Growing 8 Why is the Screening Participation Rate so Low 9 Other Limitations of Current FIT based Testing 10 Introducing ColoSTAT® by Rhythm Biosciences 11 ColoSTAT®
Slide 4: Corporate Overview
Corporate Overview Rhythm Biosciences – A medical diagnostics Financial Information technology company ASX Ticker RHY Share Price (31-Jan-2019) $0.135 Rhythm Biosciences is developing and commercialising 12-Month Range $0.13 - 0.34 Australian medical diagnostics technology for sale to national and i
Slide 5: Board and Management team
Board and Management team Experienced board & management team with proven commercial, operational and industry experience SHANE TANNER GLENN GILBERT TREVOR LOCKETT LOU PANACCIO DAVID WHITE Chairman Chief Technical Non-Executive Non-Executive Executive Officer Director Director Director • Chairman Pa
Slide 6: Introduction: Colorectal Cancer
Introduction: Colorectal Cancer • Colorectal cancer is the second most frequent cause of cancer-related deaths in the industrialized world (over 850,000 deaths annually). • It is curable in about 90% of cases if detected early, this drops to around 10% if detected late stage, once the cancer has spr
Slide 7: A global problem
A global problem Elevated risk people >50 years old remain under-screened: • Total addressable market of 250 million people in EU, USA & AU • 130+ million remain totally unscreened US EU AU Total Population between 50-74 years old 91.2M 153.4M 6.4M 251.0M Estimated screening participation rate 62.6%
Slide 8: The problem is growing
The problem is growing The global burden is expected to increase due to a growing and aging population, and lifestyle habits [1]. It is estimated that by 2030 the global burden of CRC will increase by 60% to more than 2.2 million new cases and around 1.1 million deaths [2]. 250 million Up to 60% are
Slide 9: Why is the participation rate so low?
Why is the participation rate so low? Education, Awareness and a lack of early warning cancer Symptoms contribute to the challenge in achieving targeted participation rates. Further to this, some studies are also highlighting that as the current screening process is a high involvement faecal based t
Slide 10: Other limitations of current FIT based testing
Other limitations of current FIT based testing ACCURACY COST High cost to manufacture, The FIT test only detects blood administer, market and process in the sample, it is not a the test. Aside from the test definitive test for cancer. itself, the follow up diagnostic Temperature, contamination, (col
Slide 11: Introducing ColoSTAT by Rhythm Biosciences
Introducing ColoSTAT ® by Rhythm Biosciences ColoSTAT® A simple, low cost blood test for the early detection of colorectal cancer for the global market In a recent colorectal cancer screening adherence study, 83% of unscreened participants preferred a blood test over a stool test © Rhythm Bioscience
Slide 12: ColoSTAT history
ColoSTAT® history Developed by Australia’s leading scientific research agency, the CSIRO1, over a 15 year period 2013 – 14 2005 – 06 2010 – 11 Study 4 2003 Study 1 Study 3 Lead Biomarkers Literature Initial large case Large case performance analysis /control study /control study case /control study
Slide 13: ColoSTAT effectiveness
ColoSTAT® effectiveness Accuracy of ColoSTAT® at Specificity of 95% FIT (80ug/g) (91.9% specificity) 90.00% ColoSTAT (95% specificity) 80.00% 70.00% 60.00% 50.00% 40.00% 30.00% 20.00% 10.00% 0.00% All stage cancer Stage 1 Stage 2 Stage 3 Stage 4 Fung et al. Blood-based protein biomarker panel for th
Slide 14: Competitive landscape
Competitive landscape Blood based Novigenix Epigenomics Volition Rx Colox® Epi Nu.q™ proColon® ColoSTAT ® Clinical Genomics Colvera™ Market capitalisation of existing companies with blood based screening products trade >$100m APPROACH ExactScience FIT/ Cologuard® FOBT Faecal based Molecular METHOD P
Slide 15: Milestones
Milestones Successful Strong Reagent Operating Milestones Global CSIRO IPO listing in Management developed and budget on patent partnership Achieved Dec 2017 & Board completed track position appointed 2019.20 IVD Kit Study 7 ISO 13485 Study CE & TGA Commercial Development Clinical Trial quality 6&7
Slide 16: Market size – Europe, USA, and Australia
Market size – Europe, USA, and Australia SCREENED 57.0m tests 58.6m tests 2.9m tests MARKET $2.85 bn $2.92 bn $149.1 m $5.9 bn 62.6% 38.2% 41% 52.7% 251m PEOPLE US, EU, AU US EU AU $12.5 TOTAL MARKET MARKET MARKET MARKET bn 37.4% 61.8% 59% 47.4% $1.70 bn $4.74 bn $171.8 m $6.6 bn UNSCREENED 34.1m te
Slide 17: Market Sizing vs Opportunity
Market Sizing vs Opportunity $4.6bn $7.7bn $320m Market Penetration 75% $3.4bn $5.7bn $240m $9.4 bn (participation) 50% $2.3bn $3.8bn $160m $5.9bn 25% $1.1bn $1.9bn $80m $3.1 bn US EU AU Market / Size © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL
Slide 18: Summary
Summary Rhythm Biosciences is well positioned to meet the global need for a simple low cost colorectal cancer screening test MARKET RHYTHM VALUE DELIVERY DRIVERS • 2nd biggest cancer • Rhythm developing • Experienced killer ColoSTAT®, a simple management and Blood test that can board appointed • Glo
Slide 19: Glenn Gilbert
Glenn Gilbert CEO, Rhythm Biosciences glenn.gilbert@rhythmbio.com www.rhythmbiosciences.com © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL
Rhythm Biosciences — Investor Presentation (February 2019) on 6ix